Astellas Pharma has decided the details of the incentive plan to be implemented in FY2026, specifying target participants, trust period, and method of stock acquisition. The trust period runs from May 21, 2026, to the end of August 2029, with a trust amount of approximately \u00a51.116 billion. The company will continue to operate its incentive system to enhance corporate value.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-05-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4503-20260515-01.pdf","jir_short_summary":"Astellas Pharma has decided the details of the incentive plan to be implemented in FY2026, specifying target participants, trust period, and method of stock acquisition. The trust period runs from May 21, 2026, to the end of August 2029, with a trust amount of approximately \u00a51.116 billion. The company will continue to operate its incentive system to enhance corporate value.","jir_summary":"### Future Outlook and Impact\nAstellas Pharma continues to aim to enhance management and employee motivation for increasing corporate value through its incentive system. The continuation of the system aims to improve long-term shareholder value and ensure transparency and fairness of the stock compensation scheme. The company will closely monitor the operation of the system and the results of trust fund management to ensure proper system administration.","jir_financial_highlights":"Trust amount: \u00a51,116 million (planned) (Unknown)\nTrust period: From May 21, 2026 (planned) to the end of August 2029 (planned) (Unknown)\nMethod of stock acquisition: Acquired from the stock market (Unknown)","jir_category":"","jir_hashtags":"#AstellasPharmaceutical, #IRSystem, #JapanStocks","jir_key_figures":"Trust amount: \u00a51,116 million (planned)\nTrust period: From May 21, 2026 (planned) to the end of August 2029 (planned)\nMethod of stock acquisition: Acquired from the stock market","jir_meta_title":"\u3010Astellas Pharma\u3011Long-term Incentive System Continuation\uff5cFY2026 Trust Fund Approximately \u00a51.1 Billion","jir_meta_description":"Astellas Pharma will continue its long-term incentive system in FY2026, with plans to acquire approximately \u00a51.116 billion in trust funds from the stock market. Important IR information aiming to enhance corporate value.","jir_og_title":"\u3010Astellas Pharma\u3011Long-term Incentive System Continuation\uff5cFY2026 Trust Fund Approximately \u00a51.1 Billion","jir_og_description":"Astellas Pharma is extending its long-term incentive system in FY2026. The company plans to acquire approximately \u00a51.116 billion in trust funds from the stock market, focusing on corporate value improvement.","jir_og_image_url":"\/assets\/og\/company-ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-51847","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n